O RATsIONAL'NOM VYBORE FARMAKOTERAPII PRI SAKhARNOM DIABETE 2 TIPA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Type 2 diabetes mellitus is a serious, progressive disease that is associated with the development of micro- and macrovascular complications, the prevention of which is an important goal of modern medicine. The pharmacological characteristics, the effectiveness and safety of antidiabetic therapy are discussed. It is emphasized that the use of modern sulfonylureas such as gliclazide, contribute to achieving the main goals of treatment for type 2 diabetes mellitus - maintenance of long-term metabolic control and prevention or delaying the development of vascular complications.

Full Text

Restricted Access

About the authors

E. V Biryukova

References

  1. Shaw JE, Sicree RA, Zimme PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87(1):4-14.
  2. Adeghate E, Schatiner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann NY Acad Sci 2006;1084(1):1-29.
  3. Kimmel B, Inzucchi EM. Oral agents for type 2 diabetes: an Update. Clin Diabetes 2005;23(2):64-76.
  4. Massi-Benedetti M. The Cost of Diabetes in Europe - Type II: the CODE-2 Study. Diabetolody 2002;45(7):S1-4.
  5. Дедов И.И., Шестакова М.В. Проблемы контроля качества диабетологической службы в России по данным на январь 2007 г. // Сахарный диабет 2007. № 3. С. 55-7.
  6. Malesker MA. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Pharmacotherapy 2008;28(2):193-206.
  7. Ajjan RA, Grant PJ. Cardiovascular disease pre vention in patients with type 2 diabetes: The role of oral anti-diabetic agents. Diab Vasc Dis Res 2006;3(3):147-58.
  8. Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care 2008;31(6):1260-66.
  9. Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 2011;60:1-23.
  10. Schmitz O, Lund S, Andersen PH, et al. Optimizing insulin secretogogue therapy in patients with type 2 diabetes. Diabetes Care 2002;25:342-46.
  11. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003;17:11-5.
  12. Aguilar-Bryan L, Nichols CG, Wechsler SF. Cloning of the β-cell high affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-26.
  13. Khaled AA, Sekaran M, Ikram SI. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomed Res 2010;21(2):147-55.
  14. Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann NY Acad Sci 2010;1212(1):29-40.
  15. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32(15): 1900-908.
  16. Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164.
  17. Rossing K, Christensen PK, Hovind P, et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004;66:1596.
  18. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
  19. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004; 18:113-19.
  20. Jennings PE. Vascular benefits of glicla-zide beyond glycemic control. Metabolism 2000;49:17-20.
  21. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007;50:865-79.
  22. Moen MF, Zhan M, Hsu VH. Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. Clin J Am Soc Nephrol 2009;4(6):1121-27.
  23. Sifri SA, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sul-phonylurea during Ramadan: a randomised trial. Int J Clin Pract 2011;65(11):1132-40.
  24. Aravind SR, Ismail SB, Balamurugan R. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sita-gliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin 2012;28(8):1-8.
  25. Шестакова М.В., Викулова О.К. Результаты открытой наблюдательной программы DIAMOND // Сахарный диабет 2011. № 3. С. 90-96.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies